GlobeNewsWire
21 Jun 2026, 21:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
The Phase 3 VELA-1 and VELA-2 trials showed SLK outperformed a competitor IL-17-A & F inhibitor by over 10% in HiSCR75, HiSCR100, and IHS4-100 response rates. — Direct evidence of superior efficacy against a competing drug strongly increases the likelihood of market leadership and a 'best-in-class' commercial profile.
+0.80Week 52 results for SLK in moderate-to-severe HS showed 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100. — Positive late-stage clinical data is the primary driver for biotech valuation and provides the basis for FDA approval.
+0.60Interim Week 24 data from the VELA-TEEN trial showed a ~68% HiSCR75 response rate in adolescent patients, exceeding rates seen in the adult program. — Successful expansion into the adolescent population increases the total addressable market and suggests a stronger effect in earlier-stage disease.
+0.50Continue reading
6 related stories
Search tags
Approximately 90% of patients rolled over into the two-year open-label extension (VELA-OLE), confirming the tolerability of the 120mg Q4W dosing regimen. — High retention and dosing convenience are critical for long-term patient adherence and competitive advantage in chronic disease treatment.
+0.40MoonLake Immunotherapeutics will host an Investor Day webcast on June 22, 2026, featuring an open Q&A session. — Investor days are routine events, though they can provide catalysts for further price discovery through management commentary.
+0.10Which stocks this story touches
The company reported positive Phase 3 clinical trial results showing leading efficacy and durable improvements for its HS therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
2h ago
